J Liver Cancer Search

CLOSE


J Liver Cancer > Volume 16(1); 2016 > Article
Journal of Liver Cancer 2016;16(1):1-6.
DOI: https://doi.org/10.17998/jlc.16.1.1    Published online March 31, 2016.
Treatments Other than Sorafenib for Patients with Advanced Hepatocellular Carcinoma
Do Seon Song, Si Hyun Bae
Division of Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
Copyright ©2016 by The Korean Liver Cancer Association
Abstract
Sorafenib is the standard treatment for advanced hepatocellular carcinoma according to the Barcelona Clinic Liver Cancer staging system. However, because of its unsatisfactory efficacy, adverse effects, and high cost, the use of sorafenib is limited, and other treatment modalities are required. Recent studies reported that treatment modalities other than sorafenib, such as hepatic arterial infusion chemotherapy and transarterial radioembolization, showed comparable or better response rates and survival rates than sorafenib. In this review, treatment modalities that could be used as alternatives to sorafenib will be discussed. (J Liver Cancer 2016;16:1-6)
Key Words: Hepatocellular carcinoma; Sorafenib; Hepatic arterial infusion chemotherapy; Radioembolization
NULL


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
1527 Gangnam Finance Plaza (FASTFIVE), 419 Teheran-ro, Gangnam-gu, Seoul 06160, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2019 by The Korean Liver Cancer Association. All rights reserved.

Developed in M2community

Close layer
prev next